argenx SE
corporate_fare Company Profile
argenx SE (NASDAQ:ARGX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for ARGX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for ARGX spans 6-K, SC TO-T/A, SC TO-T, 20-F.
Recent high-impact activity:
- argenx Details ALKIVIA Phase 3 Data at ACR; IMNM sBLA Planned by End-2026
- argenx to Buy Unnatural Products for $550M Upfront, Up to $1.15B Total
- argenx Q3: VYVGART Sales Up 54% to $1.7B, FY26 Spend Guidance ~$4B
- Argenx Halts Phase 3 Sjögren's Trial, Shares Plunge 14%
- argenx: FB102 Phase 2 Win in Celiac, But UNITY Sjögren's Study Fails
Financial Snapshot
Short Interest & Short Volume
3.42 days to coverFINRA reported short interest of 1,412,594 shares in ARGX as of the October 30, 2026 settlement, a 4.3% increase from the prior period — about 3.4 days to cover at its recent average daily volume. On November 20, 2026, 48.1% of ARGX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
ARGX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.